Albany, NY, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Cell separation technologies make it possible to isolate target cells from a mixture of various cells. The growing prevalence of chronic diseases has fuelled the demand for cell therapies to understand the cause of the diseases. This has augmented the growth of the global cell separation technologies market. The overall market was worth US$1.7 bn in 2012. Rapidly growing patient pool and increase in research and development activities by biotechnology companies are expected to expand the market at a CAGR of 9.7% during the period between 2013 and 2019. The global cell separation technologies market is anticipated to reach a valuation of US$3.3 bn by 2019.
Initiatives adopted by governments worldwide aimed at improving the biotechnology sector boost the growth of the global cell separation technologies market. The growing prevalence of diseases such as cancer has escalated the demand for cell therapy. However, the market is expected to be restrained by disputes related to patent rights over magnetic activated cell sorting (MACS) technique. The overall market has huge opportunity to grow with technological advancements.
Browse Research Report on Cell Separation Technologies Market: http://www.transparencymarketresearch.com/cell-separation-technologies.html
Stem Cell Research to Dominate Global Cell Separation Technologies Market
According to technology, the global cell separation technologies market has been categorized into gradient centrifugation and separation based on surface makers. The separation based on surface makers segment can be further sub-segmented into magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS). Magnetic activated cell sorting accounted for 42.5% share in the market in 2012. However, in the coming years, the demand for fluorescence activated cell sorting technology is expected to increase across cell purity sensitive specific research studies.
In terms of application, the global cell separation technologies market has been segmented into immunology, stem cell research, cancer research, and neuroscience research. In 2012, stem cell research generated the highest revenue in the market. The growing demand for cell therapy for diagnosis of diseases and the potential of stem cells in the treatment of chronic diseases will boost the demand for stem cell research in the near future.
Avail a Sample Copy of Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925
North America Dominated Global Cell Separation Technologies Market in 2012
The global cell separation technologies market has been segmented into four key regions: Asia Pacific, North America, Europe, and Rest of the World. In 2012, North America led the overall cell separation technologies market owing to availability of funds for research, higher practice of adoption of newer technologies, and developed infrastructure for research activities. Further, government support, higher healthcare infrastructure, and favourable economic conditions have propelled the growth of the regional market. However, during the forecast horizon, Asia Pacific will emerge as a lucrative regional market for cell separation technologies. The rapid growth of the regional market can be attributed to increased government funding for biotech research, growing prevalence of chronic diseases, and rise of medical tourism across countries such as Malaysia and India.
Browse Regional Analysis: http://www.europlat.org/cell-separation-technologies-quicker-and-easier-than-ever.htm
Key Players in Global Cell Separation Technologies Market
Some of the key players in the global cell separation technologies market are BD Bioscience, STEMCELL Technologies, pluriSelect GmbH, EMD Millipore, MitenyiBiotec GmbH, Terumo BCT, and Life Technologies (Thermo Fisher Scientific, Inc.).
The global cell separation technologies market is segmented as follows:
Cell Separation Technologies Market, by Technology
- Gradient centrifugation
- Separation based on surface markers
Cell Separation Technologies Market, by Application
- Stem cell research
- Immunology
- Neuroscience research
- Cancer research
About Us:
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Mr.Sudip.S 90 State Street, Suite 700 Albany, NY 12207 United States. Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com Blog: http://www.tmrblog.com/


MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 



